S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NASDAQ:ALIM

Alimera Sciences (ALIM) Stock Price, News & Analysis

$4.00
-0.21 (-4.99%)
(As of 03/18/2024 ET)
Today's Range
$3.95
$4.26
50-Day Range
$3.25
$4.21
52-Week Range
$1.30
$4.38
Volume
105,052 shs
Average Volume
81,554 shs
Market Capitalization
$209.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Alimera Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
62.5% Upside
$6.50 Price Target
Short Interest
Healthy
0.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.79mentions of Alimera Sciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.08 out of 5 stars

Medical Sector

394th out of 947 stocks

Pharmaceutical Preparations Industry

186th out of 435 stocks

ALIM stock logo

About Alimera Sciences Stock (NASDAQ:ALIM)

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

ALIM Stock Price History

ALIM Stock News Headlines

AI Cracks Open Largest Untapped Energy Reserve on Earth
This orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… 
Q4 2023 Alimera Sciences Inc Earnings Call
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
A Preview Of Alimera Sciences's Earnings
Alimera Sciences Names Elliot Maltz To Succeed Russell Skibsted As CFO
Alimera Appoints Maggie A. Pax to Its Board of Directors
Alimera Sciences Reports Third Quarter 2023 Results
See More Headlines
Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/18/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALIM
Employees
150
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$6.50
High Stock Price Target
$8.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+62.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-20,130,000.00
Pretax Margin
-24.83%

Debt

Sales & Book Value

Annual Sales
$80.75 million
Book Value
($5.72) per share

Miscellaneous

Free Float
35,915,000
Market Cap
$209.40 million
Optionable
Optionable
Beta
1.16

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Richard S. Eiswirth Jr.Mr. Richard S. Eiswirth Jr. (Age 56)
    CEO & Director
    Comp: $597.87k
  • Mr. David R. Holland (Age 60)
    Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets
    Comp: $413.5k
  • Dr. Philip Ashman Ph.D. (Age 59)
    President of International Operations
    Comp: $389.86k
  • Mr. Todd Michael Wood (Age 54)
    President of U.S. Operations
  • Mr. Elliot Maltz CPA (Age 39)
    CFO & Treasurer
  • Mr. Jason Werner
    Chief Operating Officer
  • Christopher S. Visick
    VP, General Counsel & Secretary
  • Dr. David Dyer M.D.
    Chief Retina Specialist

ALIM Stock Analysis - Frequently Asked Questions

Should I buy or sell Alimera Sciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings
or view top-rated stocks.

What is Alimera Sciences' stock price target for 2024?

2 brokerages have issued 1 year target prices for Alimera Sciences' shares. Their ALIM share price targets range from $5.00 to $8.00. On average, they predict the company's share price to reach $6.50 in the next year. This suggests a possible upside of 62.5% from the stock's current price.
View analysts price targets for ALIM
or view top-rated stocks among Wall Street analysts.

How have ALIM shares performed in 2024?

Alimera Sciences' stock was trading at $4.32 at the start of the year. Since then, ALIM stock has decreased by 7.4% and is now trading at $4.00.
View the best growth stocks for 2024 here
.

Are investors shorting Alimera Sciences?

Alimera Sciences saw a decline in short interest in February. As of February 29th, there was short interest totaling 118,600 shares, a decline of 57.2% from the February 14th total of 276,800 shares. Based on an average daily volume of 101,600 shares, the days-to-cover ratio is currently 1.2 days.
View Alimera Sciences' Short Interest
.

When is Alimera Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ALIM earnings forecast
.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) released its quarterly earnings data on Thursday, March, 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.09. The biopharmaceutical company earned $26.31 million during the quarter, compared to the consensus estimate of $25.10 million. Alimera Sciences had a negative trailing twelve-month return on equity of 130.90% and a negative net margin of 24.93%. During the same quarter in the prior year, the firm earned ($0.54) EPS.

When did Alimera Sciences' stock split?

Alimera Sciences's stock reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What guidance has Alimera Sciences issued on next quarter's earnings?

Alimera Sciences updated its FY 2024 earnings guidance on Thursday, March, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $105.0 million-, compared to the consensus revenue estimate of $103.7 million.

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

Who are Alimera Sciences' major shareholders?

Alimera Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (7.63%), AIGH Capital Management LLC (4.25%), Vanguard Group Inc. (1.24%), Vanguard Group Inc. (1.24%), Worth Venture Partners LLC (1.06%) and Balyasny Asset Management L.P. (0.08%). Insiders that own company stock include Adam Morgan, Alto Investors Lp Palo, Caligan Partners Lp, James R Largent, John Philip Jones, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan.
View institutional ownership trends
.

How do I buy shares of Alimera Sciences?

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALIM) was last updated on 3/19/2024 by MarketBeat.com Staff

From Our Partners